GlassScriptPhysician profile
Raul Alicea
NPI 1275057051
$8,960.06
in general payments reported to CMS, 2019-2025
27 companies · $1,400 in 2025
The $1,400 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,395 · 2022: $3,097 · 2023: $1,307 · 2024: $1,761 · 2025: $1,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,468.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,062.29 | 2024-2025 | Azure Xt Dr Mri Surescan, Linq II, Micra |
| Janssen Pharmaceuticals, INC | $1,023.21 | 2021-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $808.57 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $650.35 | 2021-2023 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $638.22 | 2021-2023 | |
| Amgen INC. | $516.82 | 2021-2023 | Repatha |
| Abbvie INC. | $498.50 | 2022-2024 | |
| Abbott Laboratories | $488.52 | 2023-2024 | Cardiomems, Gallant, Jot Dx |
| Boston Scientific Corporation | $439.89 | 2022-2025 | Farapulse, General - Therapies |
| Pfizer INC. | $374.01 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $280.67 | 2021-2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.12 | 2021-2023 | Jardiance |
| Esperion Therapeutics, INC. | $151.78 | 2021-2022 | |
| Biosense Webster, INC. | $139.37 | 2024 | Carto 3 |
| Amarin Pharma, INC. | $98.03 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $98.03 | 2022-2023 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $75.83 | 2021-2023 | Lifevest |
| Sanofi-Aventis U.S. LLC | $69.04 | 2022 | |
| Heartflow, INC. | $64.62 | 2022-2023 | Ffrct |
| Lantheus Medical Imaging, INC. | $56.35 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $47.72 | 2022-2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $26.11 | 2022 | |
| Novo Nordisk INC | $21.25 | 2023 | Ozempic |
| Amryt Pharma Holdings LTD | $20.54 | 2021 | |
| Edwards Lifesciences Corporation | $19.58 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $15.86 | 2021 | |
| Ani Pharmaceuticals, INC. | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Alicea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.